ClinicalTrials.gg
CompletedNCT02932319FOLOUTUpdated Apr 29, 2026

Outpatient Foley Catheter for Induction of Labor in Nulliparous for Prolonged Pregnancy

An interventional study of Foley catheter and expectative in Induction of Labour and Prolonged Pregnancy, sponsored by University Hospital, Lille. Completed at 5 sites in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

15 to 20 % of nulliparous needs an induction at term. None study has evaluated Foley catheter induction at home versus expectative in this population

02

Conditions studied

  • Induction of Labour
  • Prolonged Pregnancy

Browse trials for

Keywords

  • induction of labour
  • nulliparous
  • prolonged pregnancy
  • foley catheter
  • vaginal birth
03

In context

Pregnancy, Prolonged

30 studies on the registry are indexed under Pregnancy, Prolonged; 3 are open to participants now.

This study's enrollment of 43 is below the median of 128 across 24 interventional studies indexed under Pregnancy, Prolonged.

Browse Pregnancy, Prolonged studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • prolonged pregnancy (D+4) nulliparous no complication during pregnancy location near th hospital (20 mn by car) Bishop \< 6

Exclusion criteria

Exclusion Criteria:

  • medical history small for gestationnal age PROM Live alone
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Active comparator
    Foley catheter

    The patient will have an induction at home after 60 mn of fetal heart rate monitoring.

    Device: Foley catheter

  • Sham comparator
    Expectative

    The patient in this arm will have the actual care (expectative until the next day befor starting the induction)

    Other: expectative

Interventions

  • DeviceFoley catheter

    The Foley cathter will be inserted at term + 4 days for 24 hours.

  • Otherexpectative

    expectative until the next day befor starting the induction

06

What researchers measure

Primary outcomes

  1. Bishop score

    Measure the evolution of Bishop score,change between the randomization and the return of the patient

    Time frame: at term birth +5 days

Secondary outcomes

  1. Labour ward

    Time frame: at term birth +5 days

  2. Total dose of prostaglandin used in case of cervical ripening.

    Time frame: During labor

  3. Utilization rate of oxytocin

    Time frame: During labor

  4. Total dose of Ocytocin used or not for induction labor

    Time frame: During labor

  5. number of birth

    Time frame: between the term consultation + 4 days (randomization) and delivery time

  6. delivery rate

    Time frame: within 24 hours and 48 hours after randomization

  7. Caesarean rate

    Time frame: before labor and during labor

  8. Maternal complications

    It's the time between the term consultation + 4 days (randomization) and delivery time (day 4)

    Time frame: through study completion, at 4 day

  9. Fetal complications

    Time frame: through study completion, at 4 day

  10. Neonatal complications

    Time frame: through study completion, at 4 day

  11. Duration of hospital stay

    Time frame: through study completion, at 4 day

07

Study locations

5 sites
  • CHU de Caen
    Caen, France
  • Hôpital Jeanne de Flandre - CHRU
    Lille, France
  • CH Roubaix
    Roubaix, France
  • CHU Rouen
    Rouen, France
  • Ch Valenciennes
    Valenciennes, France
08

References and documents

Publications

  • Garabedian C, Tillouche N, Drumez E, Labreuche J, Dreyfus M, Deruelle P. Outpatient balloon catheter versus expectant management for post-term labor induction in nulliparous women: A randomized trial. J Gynecol Obstet Hum Reprod. 2024 Nov;53(9):102822. doi: 10.1016/j.jogoh.2024.102822. Epub 2024 Jul 10. PubMed 38997091 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Oct 2019, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2016
First posted
Oct 13, 2016
StartActual
Mar 31, 2017
Primary completionActual
Oct 23, 2019
CompletionActual
Oct 23, 2019
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02932319
Responsible party
Sponsor
First posted
Oct 13, 2016
Start date
Mar 31, 2017
Primary completion
Oct 23, 2019
Completion
Oct 23, 2019
Last update
Apr 29, 2026

Study contacts

Charles Garabedian, MD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion